Percutaneous bioprosthetic aortic valve durability: results a single center after ten years of follow-up ago
Abstract The durability of transcatheter heart valves and long-term clinical outcomes are unknown. The aim of this study was to evaluate clinical and hemodynamic outcomes 10 years after Transcatheter Aortic Valve Implantation (TAVI). Methods Between April 2008 and December 2011, 230 patients under...
Gespeichert in:
| Veröffentlicht in: | European heart journal 2021-10, Vol.42 (Supplement_1) |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | |
| container_title | European heart journal |
| container_volume | 42 |
| creator | Munoz-Garcia, M Munoz-Garcia, E Munoz Garcia, A J Dominguez-Franco, A J Alonso-Briales, J H Jimenez-Navarro, M F Hernandez-Garcia, J M Gomez-Doblas, J J |
| description | Abstract
The durability of transcatheter heart valves and long-term clinical outcomes are unknown. The aim of this study was to evaluate clinical and hemodynamic outcomes 10 years after Transcatheter Aortic Valve Implantation (TAVI).
Methods
Between April 2008 and December 2011, 230 patients underwent TAVI for the treatment of severe symptomatic aortic stenosis with the auto-expandable prosthesis.
Results
The mean age, logistic EuroSCORE and STS score were 79.3±6.4 years, 19.8±13% and 6.8±5% respectively. Mean aortic valve gradient decreased from 49.8±15 mm Hg to 8.6±3.8 mmHg after TAVI, to 11.1±9 mm Hg at 5 years, and 25.7±12 mmHg at 7 years (p for post-TAVI trend 0.03). Mean aortic valve area increased from 0.63±0.16 cm2 to 1.57±0.3cm2 after TAVI to 1.48±0.2 at 5 years and 0.87±0.3 cm2 at 7 years (p for post-TAVI trend 0.01). Mean left ventricular ejection fraction increased from 61.1±15% to 65.5±11% after TAVI, to 58.2±17% at 5 years and 57.2±8% at 7 years (p for post-TAVI trend 0.001).
The total mortality after a mean of 53±34 months was 73% and 34.4% was cardiovascular mortality. Survival rates at 1 to 10 years were at 86%, 75.4%, 64.9%, 59.6%, 52.6%, 33.1%, 24.9%, 20.7%, 10.4% and 10.4% respectively. Only 4 patients had severe prosthetic valve dysfunction (severe stenosis and moderate-severe transvalvular regurgitation). Median survival time after TAVI was 6 years (95% confidence interval [CI]: 5.89 to 6.28), and the risk of death was significantly increased in patients with frailty (adjusted hazard ratio [HR]: 1.874; 95% CI: 1.028 to 3.418), p=0.040, Charlson index [HR=1.212 (95% CI: 1.094–1.341), p |
| doi_str_mv | 10.1093/eurheartj/ehab724.1575 |
| format | Article |
| fullrecord | <record><control><sourceid>oup_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1093_eurheartj_ehab724_1575</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/eurheartj/ehab724.1575</oup_id><sourcerecordid>10.1093/eurheartj/ehab724.1575</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1375-9343d5fc9978580f0f3bfe596bed8be2f4d41cca2df9c120f86f55e423f7da483</originalsourceid><addsrcrecordid>eNqNkM1KAzEUhYMoWH9eQfIC0yaZJJO4k-IfFHSh4G7IZG7aKXEyJJlK394OLa7dnLP6Lvd8CN1RMqdElwsY4wZMzNsFbExTMT6nohJnaEYFY4WWXJyjGaFaFFKqr0t0ldKWEKIklTPk3yHaMZsewphw04UhhpQ3kDuLTYhT7YzfAW7HaJrOd3l_jyOk0eeEDU5dv_aALfQZIjZuygw93h8eSjg47IL34acYB2zW4QZdOOMT3J76Gn0-PX4sX4rV2_Pr8mFVWFpWotAlL1vhrNaVEoo44srGgdCygVY1wBxvObXWsNZpSxlxSjohgLPSVa3hqrxG8njXHsakCK4eYvdt4r6mpJ6c1X_O6pOzenJ2AOkRDOPwX-YXhjN4NA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Percutaneous bioprosthetic aortic valve durability: results a single center after ten years of follow-up ago</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Munoz-Garcia, M ; Munoz-Garcia, E ; Munoz Garcia, A J ; Dominguez-Franco, A J ; Alonso-Briales, J H ; Jimenez-Navarro, M F ; Hernandez-Garcia, J M ; Gomez-Doblas, J J</creator><creatorcontrib>Munoz-Garcia, M ; Munoz-Garcia, E ; Munoz Garcia, A J ; Dominguez-Franco, A J ; Alonso-Briales, J H ; Jimenez-Navarro, M F ; Hernandez-Garcia, J M ; Gomez-Doblas, J J</creatorcontrib><description>Abstract
The durability of transcatheter heart valves and long-term clinical outcomes are unknown. The aim of this study was to evaluate clinical and hemodynamic outcomes 10 years after Transcatheter Aortic Valve Implantation (TAVI).
Methods
Between April 2008 and December 2011, 230 patients underwent TAVI for the treatment of severe symptomatic aortic stenosis with the auto-expandable prosthesis.
Results
The mean age, logistic EuroSCORE and STS score were 79.3±6.4 years, 19.8±13% and 6.8±5% respectively. Mean aortic valve gradient decreased from 49.8±15 mm Hg to 8.6±3.8 mmHg after TAVI, to 11.1±9 mm Hg at 5 years, and 25.7±12 mmHg at 7 years (p for post-TAVI trend 0.03). Mean aortic valve area increased from 0.63±0.16 cm2 to 1.57±0.3cm2 after TAVI to 1.48±0.2 at 5 years and 0.87±0.3 cm2 at 7 years (p for post-TAVI trend 0.01). Mean left ventricular ejection fraction increased from 61.1±15% to 65.5±11% after TAVI, to 58.2±17% at 5 years and 57.2±8% at 7 years (p for post-TAVI trend 0.001).
The total mortality after a mean of 53±34 months was 73% and 34.4% was cardiovascular mortality. Survival rates at 1 to 10 years were at 86%, 75.4%, 64.9%, 59.6%, 52.6%, 33.1%, 24.9%, 20.7%, 10.4% and 10.4% respectively. Only 4 patients had severe prosthetic valve dysfunction (severe stenosis and moderate-severe transvalvular regurgitation). Median survival time after TAVI was 6 years (95% confidence interval [CI]: 5.89 to 6.28), and the risk of death was significantly increased in patients with frailty (adjusted hazard ratio [HR]: 1.874; 95% CI: 1.028 to 3.418), p=0.040, Charlson index [HR=1.212 (95% CI: 1.094–1.341), p<0.001], and age [HR=1.03; (95% CI: 1.001–1.062), p=0.049].
Conclusions
In our center, the transcatheter aortic valve implantation in patients at high surgical risk, presented favourable clinical outcomes and hemodynamic performance after ten years of follow-up.
FUNDunding Acknowledgement
Type of funding sources: None.</description><identifier>ISSN: 0195-668X</identifier><identifier>EISSN: 1522-9645</identifier><identifier>DOI: 10.1093/eurheartj/ehab724.1575</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>European heart journal, 2021-10, Vol.42 (Supplement_1)</ispartof><rights>Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2021. For permissions, please email: journals.permissions@oup.com. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>Munoz-Garcia, M</creatorcontrib><creatorcontrib>Munoz-Garcia, E</creatorcontrib><creatorcontrib>Munoz Garcia, A J</creatorcontrib><creatorcontrib>Dominguez-Franco, A J</creatorcontrib><creatorcontrib>Alonso-Briales, J H</creatorcontrib><creatorcontrib>Jimenez-Navarro, M F</creatorcontrib><creatorcontrib>Hernandez-Garcia, J M</creatorcontrib><creatorcontrib>Gomez-Doblas, J J</creatorcontrib><title>Percutaneous bioprosthetic aortic valve durability: results a single center after ten years of follow-up ago</title><title>European heart journal</title><description>Abstract
The durability of transcatheter heart valves and long-term clinical outcomes are unknown. The aim of this study was to evaluate clinical and hemodynamic outcomes 10 years after Transcatheter Aortic Valve Implantation (TAVI).
Methods
Between April 2008 and December 2011, 230 patients underwent TAVI for the treatment of severe symptomatic aortic stenosis with the auto-expandable prosthesis.
Results
The mean age, logistic EuroSCORE and STS score were 79.3±6.4 years, 19.8±13% and 6.8±5% respectively. Mean aortic valve gradient decreased from 49.8±15 mm Hg to 8.6±3.8 mmHg after TAVI, to 11.1±9 mm Hg at 5 years, and 25.7±12 mmHg at 7 years (p for post-TAVI trend 0.03). Mean aortic valve area increased from 0.63±0.16 cm2 to 1.57±0.3cm2 after TAVI to 1.48±0.2 at 5 years and 0.87±0.3 cm2 at 7 years (p for post-TAVI trend 0.01). Mean left ventricular ejection fraction increased from 61.1±15% to 65.5±11% after TAVI, to 58.2±17% at 5 years and 57.2±8% at 7 years (p for post-TAVI trend 0.001).
The total mortality after a mean of 53±34 months was 73% and 34.4% was cardiovascular mortality. Survival rates at 1 to 10 years were at 86%, 75.4%, 64.9%, 59.6%, 52.6%, 33.1%, 24.9%, 20.7%, 10.4% and 10.4% respectively. Only 4 patients had severe prosthetic valve dysfunction (severe stenosis and moderate-severe transvalvular regurgitation). Median survival time after TAVI was 6 years (95% confidence interval [CI]: 5.89 to 6.28), and the risk of death was significantly increased in patients with frailty (adjusted hazard ratio [HR]: 1.874; 95% CI: 1.028 to 3.418), p=0.040, Charlson index [HR=1.212 (95% CI: 1.094–1.341), p<0.001], and age [HR=1.03; (95% CI: 1.001–1.062), p=0.049].
Conclusions
In our center, the transcatheter aortic valve implantation in patients at high surgical risk, presented favourable clinical outcomes and hemodynamic performance after ten years of follow-up.
FUNDunding Acknowledgement
Type of funding sources: None.</description><issn>0195-668X</issn><issn>1522-9645</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNqNkM1KAzEUhYMoWH9eQfIC0yaZJJO4k-IfFHSh4G7IZG7aKXEyJJlK394OLa7dnLP6Lvd8CN1RMqdElwsY4wZMzNsFbExTMT6nohJnaEYFY4WWXJyjGaFaFFKqr0t0ldKWEKIklTPk3yHaMZsewphw04UhhpQ3kDuLTYhT7YzfAW7HaJrOd3l_jyOk0eeEDU5dv_aALfQZIjZuygw93h8eSjg47IL34acYB2zW4QZdOOMT3J76Gn0-PX4sX4rV2_Pr8mFVWFpWotAlL1vhrNaVEoo44srGgdCygVY1wBxvObXWsNZpSxlxSjohgLPSVa3hqrxG8njXHsakCK4eYvdt4r6mpJ6c1X_O6pOzenJ2AOkRDOPwX-YXhjN4NA</recordid><startdate>20211012</startdate><enddate>20211012</enddate><creator>Munoz-Garcia, M</creator><creator>Munoz-Garcia, E</creator><creator>Munoz Garcia, A J</creator><creator>Dominguez-Franco, A J</creator><creator>Alonso-Briales, J H</creator><creator>Jimenez-Navarro, M F</creator><creator>Hernandez-Garcia, J M</creator><creator>Gomez-Doblas, J J</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20211012</creationdate><title>Percutaneous bioprosthetic aortic valve durability: results a single center after ten years of follow-up ago</title><author>Munoz-Garcia, M ; Munoz-Garcia, E ; Munoz Garcia, A J ; Dominguez-Franco, A J ; Alonso-Briales, J H ; Jimenez-Navarro, M F ; Hernandez-Garcia, J M ; Gomez-Doblas, J J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1375-9343d5fc9978580f0f3bfe596bed8be2f4d41cca2df9c120f86f55e423f7da483</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Munoz-Garcia, M</creatorcontrib><creatorcontrib>Munoz-Garcia, E</creatorcontrib><creatorcontrib>Munoz Garcia, A J</creatorcontrib><creatorcontrib>Dominguez-Franco, A J</creatorcontrib><creatorcontrib>Alonso-Briales, J H</creatorcontrib><creatorcontrib>Jimenez-Navarro, M F</creatorcontrib><creatorcontrib>Hernandez-Garcia, J M</creatorcontrib><creatorcontrib>Gomez-Doblas, J J</creatorcontrib><collection>CrossRef</collection><jtitle>European heart journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Munoz-Garcia, M</au><au>Munoz-Garcia, E</au><au>Munoz Garcia, A J</au><au>Dominguez-Franco, A J</au><au>Alonso-Briales, J H</au><au>Jimenez-Navarro, M F</au><au>Hernandez-Garcia, J M</au><au>Gomez-Doblas, J J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Percutaneous bioprosthetic aortic valve durability: results a single center after ten years of follow-up ago</atitle><jtitle>European heart journal</jtitle><date>2021-10-12</date><risdate>2021</risdate><volume>42</volume><issue>Supplement_1</issue><issn>0195-668X</issn><eissn>1522-9645</eissn><abstract>Abstract
The durability of transcatheter heart valves and long-term clinical outcomes are unknown. The aim of this study was to evaluate clinical and hemodynamic outcomes 10 years after Transcatheter Aortic Valve Implantation (TAVI).
Methods
Between April 2008 and December 2011, 230 patients underwent TAVI for the treatment of severe symptomatic aortic stenosis with the auto-expandable prosthesis.
Results
The mean age, logistic EuroSCORE and STS score were 79.3±6.4 years, 19.8±13% and 6.8±5% respectively. Mean aortic valve gradient decreased from 49.8±15 mm Hg to 8.6±3.8 mmHg after TAVI, to 11.1±9 mm Hg at 5 years, and 25.7±12 mmHg at 7 years (p for post-TAVI trend 0.03). Mean aortic valve area increased from 0.63±0.16 cm2 to 1.57±0.3cm2 after TAVI to 1.48±0.2 at 5 years and 0.87±0.3 cm2 at 7 years (p for post-TAVI trend 0.01). Mean left ventricular ejection fraction increased from 61.1±15% to 65.5±11% after TAVI, to 58.2±17% at 5 years and 57.2±8% at 7 years (p for post-TAVI trend 0.001).
The total mortality after a mean of 53±34 months was 73% and 34.4% was cardiovascular mortality. Survival rates at 1 to 10 years were at 86%, 75.4%, 64.9%, 59.6%, 52.6%, 33.1%, 24.9%, 20.7%, 10.4% and 10.4% respectively. Only 4 patients had severe prosthetic valve dysfunction (severe stenosis and moderate-severe transvalvular regurgitation). Median survival time after TAVI was 6 years (95% confidence interval [CI]: 5.89 to 6.28), and the risk of death was significantly increased in patients with frailty (adjusted hazard ratio [HR]: 1.874; 95% CI: 1.028 to 3.418), p=0.040, Charlson index [HR=1.212 (95% CI: 1.094–1.341), p<0.001], and age [HR=1.03; (95% CI: 1.001–1.062), p=0.049].
Conclusions
In our center, the transcatheter aortic valve implantation in patients at high surgical risk, presented favourable clinical outcomes and hemodynamic performance after ten years of follow-up.
FUNDunding Acknowledgement
Type of funding sources: None.</abstract><pub>Oxford University Press</pub><doi>10.1093/eurheartj/ehab724.1575</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0195-668X |
| ispartof | European heart journal, 2021-10, Vol.42 (Supplement_1) |
| issn | 0195-668X 1522-9645 |
| language | eng |
| recordid | cdi_crossref_primary_10_1093_eurheartj_ehab724_1575 |
| source | Oxford University Press Journals All Titles (1996-Current); Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | Percutaneous bioprosthetic aortic valve durability: results a single center after ten years of follow-up ago |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T02%3A29%3A45IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Percutaneous%20bioprosthetic%20aortic%20valve%20durability:%20results%20a%20single%20center%20after%20ten%20years%20of%20follow-up%20ago&rft.jtitle=European%20heart%20journal&rft.au=Munoz-Garcia,%20M&rft.date=2021-10-12&rft.volume=42&rft.issue=Supplement_1&rft.issn=0195-668X&rft.eissn=1522-9645&rft_id=info:doi/10.1093/eurheartj/ehab724.1575&rft_dat=%3Coup_cross%3E10.1093/eurheartj/ehab724.1575%3C/oup_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/eurheartj/ehab724.1575&rfr_iscdi=true |